NASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis $1.00 +0.14 (+15.67%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About ABVC BioPharma Stock (NASDAQ:ABVC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ABVC BioPharma alerts:Sign Up Key Stats Today's Range$0.85▼$1.0350-Day Range$0.71▼$2.0252-Week Range$0.71▼$3.40Volume179,093 shsAverage Volume107,579 shsMarket Capitalization$26.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens. The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy. Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.AI Generated. May Contain Errors. Read More ABVC BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreABVC MarketRank™: ABVC BioPharma scored higher than 7% of companies evaluated by MarketBeat, and ranked 883rd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageABVC BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about ABVC BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ABVC BioPharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ABVC BioPharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioABVC BioPharma has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ABVC BioPharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.99% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently decreased by 2.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABVC BioPharma does not currently pay a dividend.Dividend GrowthABVC BioPharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 1 article on an average week.MarketBeat Follows1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABVC BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.38% of the stock of ABVC BioPharma is held by institutions.Read more about ABVC BioPharma's insider trading history. Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVC Stock News HeadlinesABVC BioPharma (NASDAQ:ABVC) Trading 4.7% Higher - Here's What HappenedSeptember 3 at 2:00 AM | americanbankingnews.comABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC ShareholdersJune 23, 2026 | finance.yahoo.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 3 at 1:00 AM | Altimetry (Ad)ABVC BioPharma Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comABVC BioPharma Reports 2025 Form 10-KMarch 4, 2026 | finance.yahoo.comABVC BioPharma Provides Corporate and Structural UpdateFebruary 24, 2026 | finance.yahoo.comABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United StatesDecember 2, 2025 | finance.yahoo.comABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods ...November 26, 2025 | finance.yahoo.comSee More Headlines ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed this year? ABVC BioPharma's stock was trading at $2.13 at the start of the year. Since then, ABVC stock has decreased by 53.1% and is now trading at $1.00. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) released its earnings results on Wednesday, August, 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.37. When did ABVC BioPharma's stock split? Shares of ABVC BioPharma reverse split on Tuesday, July 25th 2023.The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an initial public offering on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ABVC BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS). Company Calendar Last Earnings8/12/2026Today9/03/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 10 days, ABVC's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ABVC CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees30Year Founded2002Profitability EPS (Trailing Twelve Months)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.91 million Net MarginsN/A Pretax Margin-954.77% Return on Equity-47.68% Return on Assets-30.97% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$510 thousand Price / Sales52.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book2.17Miscellaneous Outstanding Shares26,650,000Free Float21,590,000Market Cap$26.65 million OptionableNot Optionable Beta0.61 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ABVC) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
